Navigation Links
Immucor Submits 10-Day Response to FDA; Establishes Product Surveillance and Improvement Department
Date:7/13/2009

NORCROSS, Ga., July 13 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced the submission of its formal 10 working day response to the Food and Drug Administration's ("FDA") administrative action, which was announced on June 26, 2009.

This formal 10-day response reiterates the Company's commitment to implement corrective actions that not only address the FDA's noted deficiencies but also establish a world-class quality system. The Company will provide its detailed remediation plan and timelines in its 30 working day response to the FDA no later than August 11, 2009.

"We take our regulatory responsibilities very seriously. We began our Quality Process Improvement Project in early 2009 to bring our quality system up to world-class standards," stated Dr. Gioacchino De Chirico, Immucor's President and Chief Executive Officer. "We remain committed to completing this Project as quickly as possible."

Immucor previously announced that it had received a notice of intent to revoke its biologics license from the FDA with respect to its Reagent Red Blood Cells and Anti-E (Monoclonal) Blood Grouping Reagent products. This administrative action was based on a January 2009 inspection. The notice has a revised effective date of June 30, 2009.

The FDA has not ordered the recall or banned the sale of any of the Company's products.

New Product Surveillance and Improvement Department Established

The Company also announced today the creation of a Product Surveillance and Improvement Department to support the quality system initiative underway. With a focus on product quality, this new department will provide a single internal focal point to monitor quality issues, whether identified through internal or external sources, and initiate the appropriate corrective actions.

"We will continue to evaluate our operations and organization to ensure they are in line with our commitment to develop high quality systems," stated Dr. De Chirico. "Our new Product Surveillance and Improvement Department is an important example of our drive to modernize our quality approach."

About Immucor

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at www.immucor.com.


'/>"/>
SOURCE Immucor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Immucor to Announce Fiscal Fourth Quarter Financial Results on Thursday, July 23, 2009
2. Immucor Announces Fiscal Year 2010 Guidance
3. Immucor to Announce Fiscal 2010 Guidance on Monday, June 1, 2009
4. Immucor to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
5. Immucor Receives Subpoena From Department of Justice
6. Immucor Announces Fiscal Third Quarter Results
7. Immucor Announces New Vice President, Operations
8. Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance
9. Immucor Closes BioArray Acquisition
10. Immucor Schedules Fiscal 2009 Guidance Call
11. Immucor Responding to FDA Warning Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... ... Allegheny Health Network (AHN) officials today announced a bold new step to ... services in the greater Pittsburgh region. Starting January 23, patients who call AHN by ... same afternoon. , AHN is the first healthcare provider in the ...
(Date:1/19/2017)... GA (PRWEB) , ... January 19, 2017 , ... ... offers asset protection and financial planning services to communities throughout eastern Georgia, is ... fight against heart disease. , Heart disease kills more Americans every year than ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... locally owned insurance agency which serves Lawrenceville, New Jersey and the surrounding area, ... , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease ...
(Date:1/19/2017)... ... 19, 2017 , ... Attorney Robert “RC” Pate , founder of The ... the Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric ... firsthand the effect of the critical funding gap for research into pediatric cancer research. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017  Abaxis, Inc. (NasdaqGS: ABAX ), ... and consumables for the medical and veterinary markets worldwide, ... results for the third quarter fiscal year 2017, ended ... p.m. ET on Thursday, January 26, 2017.  The Company ... year 2017 after the market closes on Thursday, January ...
(Date:1/19/2017)... -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the German ... Germany , has purchased a MRIdian ... Clinic Heidelberg as part of its initiative for MRI-based ... be headed by Medical Director and Professor Jürgen Debus, ... German Cancer Research Center (DKFZ), the Heidelberg Heavy Ion ...
(Date:1/19/2017)... England , January 19, 2017 ... and Otsuka in the Milner Therapeutics Consortium   ... scientists in Cambridge   ... (NYSE: PFE ) as a partner to ... the Consortium, which enables the efficient transfer of materials ...
Breaking Medicine Technology: